Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Qilu Says PD-1/CTLA-4 Combo Effective Against Cervical Cancer

publication date: Mar 4, 2024

Jinan Qilu Pharma presented data from a Phase II trial showing that its QL1706 combination therapy of a PD-1 and CTLA-4 was effective against cervical cancer. The combination met its primary endpoint with an objective response rate of 33.8%. In August 2023, China’s NMPA accepted a new drug application for QL1706, the first MabPair product targeting PD-1 and CTLA-4 worldwide. Qilu will present the trial data at The European Society of Gynecological Oncology (ESGO) 2024 Conference later this week. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here